Lantheus Holdings (LNTH) Total Current Liabilities (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Total Current Liabilities of $333.2 million for Q1 2026, up 34.34% year-over-year from $248.0 million in Q1 2025, and little changed quarter-over-quarter from $333.4 million in Q4 2025.
Lantheus Holdings (LNTH) Total Current Liabilities (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Total Current Liabilities for 13 consecutive years, with $333.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 34.34% year-over-year to $333.2 million; the TTM figure through Mar 2026 stood at $333.2 million (up 34.34% YoY), while the FY2025 annual figure was $333.4 million, up 38.62% from the prior year.
- Total Current Liabilities steadied at $333.2 million in Q1 2026 per LNTH's latest filing, from $333.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $784.1 million in Q3 2024 and bottomed at $154.0 million in Q2 2023.
- Historically, Total Current Liabilities has averaged $278.9 million across 5 years, with a median of $247.7 million in 2022.
- Annual changes were most pronounced in 2024 — Total Current Liabilities surged 343.98% — and 2025, when it plunged 55.76%.
- Lantheus Holdings' Total Current Liabilities stood at $247.7 million in 2022, then slipped by 24.36% to $187.4 million in 2023, then gained by 28.38% to $240.5 million in 2024, then surged by 38.62% to $333.4 million in 2025, then decreased by 0.08% to $333.2 million in 2026.
- Business Quant data shows LNTH's Total Current Liabilities at $333.2 million in Q1 2026, $333.4 million in Q4 2025, and $346.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 335.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 335.68 Mn |
| Mar 31, 2026 | 333.17 Mn |
| Dec 31, 2025 | 333.42 Mn |
| Sep 30, 2025 | 346.84 Mn |
| Jun 30, 2025 | 280.13 Mn |
| Mar 31, 2025 | 248.00 Mn |
| Dec 31, 2024 | 240.53 Mn |
| Sep 30, 2024 | 784.08 Mn |
| Jun 30, 2024 | 263.29 Mn |
| Mar 31, 2024 | 237.20 Mn |
| Dec 31, 2023 | 187.35 Mn |
| Sep 30, 2023 | 176.60 Mn |
| Jun 30, 2023 | 154.04 Mn |
| Mar 31, 2023 | 276.39 Mn |
| Dec 31, 2022 | 247.70 Mn |
| Sep 30, 2022 | 235.98 Mn |
| Jun 30, 2022 | 219.02 Mn |
| Mar 31, 2022 | 177.66 Mn |
| Dec 31, 2021 | 90.50 Mn |
| Sep 30, 2021 | 76.90 Mn |